Gritstone Oncology Inc

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Gritstone Oncology reports strong financials and promising advancements in immunotherapy

Gritstone Oncology Inc showcases financial stability, progress in cancer immunotherapy, and advancements in infectious disease programs. Challenges include data requirements for ongoing studies, while opportunities lie in upcoming data presentations and exploring novel vaccine concepts.

Gritstone Oncology excels in Q1 with promising GRANITE program and samRNA advancements

Gritstone Oncology's Q1 2023 earnings call highlighted strong financials, progress in the GRANITE program, and advancements in the samRNA platform. Challenges include endpoint selection for Phase 3 study and managing pseudo progressors. Opportunities lie in combining immunotherapies for KRAS mutations and exploring adjuvant settings.

Gritstone Oncology reports positive Q1 results and eyes market expansion

Gritstone Oncology's Q1 2024 performance showcased positive outcomes in the GRANITE program and financial stability through strategic funding.
The company's strengths lie in promising immune responses, encouraging PFS data, and a proactive approach to clinical program advancement.
Challenges include data gaps in patient groups and uncertainties around future consortium data, while opportunities abound in market expansion and upcoming data releases.
Overall, Gritstone Oncology's focus on innovative cancer vaccine programs and financial prudence positions them well for future growth and clinical success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gritstone bio Inc. (GRTS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Gritstone bio: Q4 2023 Data Readout Is Going To Be Major Inflection Point.

Gritstone bio: Q4 2023 Data Readout Is Going To Be Major Inflection Point

-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including variant cross-reactive nAb, in previously unvaccinated (“vaccine-naïve”) South African subjects -- -- Updated CORAL-BOOST: Boost samRNA vaccine elicits robust nAbs that persist for at least 6 months regardless of primary series (adenovirus or mRNA) --

Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)

-- Longitudinal analysis of GRANITE recipients (personalized vaccine candidate now in Phase 2/3 for MSS-CRC) demonstrates vaccine-elicited priming and boosting of antigen-specific T cell populations associated with conversion of “cold” to “hot” tumors and molecular responses -- -- Advances in EDGE™ models (Gritstone's AI-driven neoantigen prediction platform) enable best-in-class prediction of class II HLA-presented neoantigens that could drive CD4 + T cell responses --

Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting

EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), taking place April 15-18, 2023 in Copenhagen, Denmark. Both presentations are from the company's CORAL program, which is evaluating various self-amplifying mRNA (samRNA) vaccine candidates targeting Spike in addition to other viral genes of SARS-CoV-2. The program aims to serve as proof-of-concept for Gritstone's infectious disease vaccine approach and the potential application of samRNA against infectious diseases.

Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023

EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced multiple presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023 in Orlando, Florida. The poster presentations will address the company's proprietary neoantigen prediction capabilities (EDGE™) and “off-the-shelf" neoantigen vaccine program, SLATE. The minisymposium will review results from the Phase 1/2 study of GRANITE, the company's fully-individualized neoantigen vaccine program which is now in a randomized Phase 2/3 study for first-line microsatellite-stable colorectal cancer (MSS-CRC).

Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting

Gritstone bio Inc. (NASDAQ:GRTS ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew Allen - Co-Founder, President, CEO and Director Vassiliki Economides - Executive VP and CFO Karin Jooss - Head of Research and Development Conference Call Participants Marc Frahm - TD Cowen Ted Tenthoff - Piper Sandler Mayank Mamtani - B. Riley Securities Arthur He - H.

Gritstone bio Inc. (GRTS) Q4 2022 Results - Earnings Call Transcript

-- Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals from “off-the-shelf” vaccine program (SLATE) consistent with those from GRANITE; randomized study of SLATE in patients with newly-diagnosed metastatic cancer to initiate in 2H 2023 --

Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Gritstone's Co-founder, President and Chief Executive Officer will participate in the “Novel Immuno-Oncology” panel at the Cowen 43rd Annual Healthcare Conference on March 6, 2023.

Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference

-- NCI will lead the Phase 1 study using Gritstone's proprietary “off the shelf” vaccine technology for mutant KRAS solid tumors -- -- NCI will lead the Phase 1 study using Gritstone's proprietary “off the shelf” vaccine technology for mutant KRAS solid tumors --

Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination

Gritstone stock has tanked since the company's IPO but 2023 could be the year this biotech delivers. A personalised cancer vaccine specialist at heart, Gritstone's pivot into developing a COVID vaccine may have been an unwelcome distraction.

Gritstone bio: Keep An Eye On This Discounted Cancer Vaccine Developer In 2023

EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference occurring January 9-12, 2023 in San Francisco. The presentation will take place on Thursday, January 12, 2023 from 9:45 - 10:25 AM Pacific Time in Elizabethan A conference room.

Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference

EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the company's Board of Directors granted five employees nonqualified stock options to purchase an aggregate of 46,950 shares of its common stock with an exercise price of $2.69, which is equal to the closing price of Gritstone's common stock on December 6, 2022, the date of the grant. These stock options are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

-- Patents support Gritstone's pioneering work in the application of next-generation samRNA vaccine technology in oncology and infectious disease -- -- Patents support Gritstone's pioneering work in the application of next-generation samRNA vaccine technology in oncology and infectious disease --

Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)

EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that Gritstone management will participate in the following upcoming investor conferences.

Gritstone to Participate in Upcoming Investor Conferences

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 10.26% and 22.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Gritstone bio Inc. (GRTS) Reports Q3 Loss, Lags Revenue Estimates

-- Two Phase 1 CORAL (SARS-CoV-2) studies deliver positive results, provide further proof-of-concept for application of self-amplifying mRNA (samRNA) as infectious disease vaccine platform -- -- Initial Phase 2 data from KRAS-directed SLATE ("off-the-shelf" neoantigen program) show similar signals in non-small cell lung cancer (NSCLC) as GRANITE (individualized neoantigen program) in colorectal cancer (CRC) --

Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update

Gritstone bio Inc. (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Should You Buy?

EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that it has executed a securities purchase agreement to sell, through a private investment in public equity (PIPE) financing, 6,637,165 shares of its common stock at a price of $2.26 per share of common stock and 13,274,923 pre-funded warrants to purchase up to 13,274,923 shares of common stock at a price of $2.2599 per pre-funded warrant for aggregate gross proceeds of approximately $45.0 million, before deducting placement agent fees and offering expenses. Each pre-funded warrant will have an exercise price of $0.0001 per share, will be exercisable immediately, and will be exercisable until exercised in full. The transaction is expected to close on October 27, 2022, subject to customary closing conditions. Gritstone intends to use the net proceeds from the PIPE financing to fund the ongoing clinical development of oncology and infectious disease programs and for general corporate purposes.

Gritstone bio Announces Private Placement of $45.0 Million

-- New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination -- -- Interim results from CORAL-CEPI show good tolerability and immunogenicity in all vaccine-naïve subjects dosed --

Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases

Gritstone bio results from the phase 1/2 study, using SLATE vaccines in treating patients with KRAS mutant MSS-CRC and NSCLC, were positive with a 39% molecular response observed. Molecular response achieved in KRAS mutant NSCLC patients led to a doubling of overall survival; previous checkpoint inhibitor literature and another study using GRANITE proved this correlation.

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst

Aprea Therapeutics

Ardelyx

Seelos Therapeutics

Red Hot Biotech Penny Stocks To Watch Right Now The post Why The Stock Market Is Down Today & 4 Penny Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why The Stock Market Is Down Today & 4 Penny Stocks To Watch

-- SLATE vaccines (version 1 and SLATE-KRAS) demonstrate early evidence of efficacy with a 39% molecular response rate in evaluable patients with late-line microsatellite-stable colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC) -- -- Molecular response, as measured by reduction in circulating tumor DNA (ctDNA) from baseline, demonstrates a correlation with overall survival (OS) in NSCLC, consistent with industry literature --

Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022

EMERYVILLE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that management will present at the 2022 Wells Fargo Healthcare Conference, taking place September 7-9, 2022, in Boston, MA, and participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12-14, 2022, in New York, NY. The events will also be available via webcast. Please find additional details about the events below.

Gritstone to Participate in Two Upcoming Investor Conferences

-- Paper reports that Gritstone's tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells, including cytotoxic CD8+ T cells -- -- T cells linked to molecular responses in advanced colorectal cancer (CRC) patients and associated with extended overall survival, which has been observed in follow-up to the Phase 1/2 study --

News for Gritstone Oncology Inc Stock (GRTS)